Gaithersburg, MD, USA and Suzhou Biobay, China, September 6, 2022 – Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that Dr. Patrick Lu, PhD, founder, Chairman of the Board, Executive Director, President, and CEO of Sirnaomics, will present at the 3rd Annual Jefferies Asia Forum that will be held on September 8, 2022.

Following the presentation, there will be scheduled investor meetings at the conference. If any investors are interested in having meetings on an individual basis, please contact our Investor Relations by email: [email protected].

3rd Annual Jefferies Asia Forum
Date:  September 8, 2022.
Time: 09:00 AM HKT
Presentation link: https://wsw.com/webcast/jeff252/panel42/2133432 
Kindly remind: Participants need to pre-register to gain the ascces to the presentation. 

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:

Investor Relations:

Nigel Yip

Chief Financial Officer, China, Sirnaomics

Email: [email protected]

US Media Contact:

Mark Corbae

Tel: +1 203 682 8288

Email: [email protected]

Asia Media Contact:

Bunny Lee

Tel: +852 3150 6707

Email: [email protected]